Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14429222 | 1.00 | KMT2A (0.42) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL20889066 | 0.85 | KMT2A (0.42) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL23941179 | 0.83 | RCE1 (0.39) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL9837878 | 0.83 | CA1 (0.45) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL18639180 | 0.80 | ALDH1A1 (0.44) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL20009805 | 0.80 | RCE1 (0.47) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL14429223 | 0.80 | HTT (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL14429242 | 0.80 | HTT (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL17898633 | 0.80 | MAPT (0.43) | KMT2AHTTCA1CA2CA7 | |
| SCHEMBL23989405 | 0.79 | KMT2A (0.45) | KMT2AHTTCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | IDENIX PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185063-A1 | Seven-membered ring nucleosides | NSUN2, NSUN3, HAVCR2 | KMT2A 3044/4885HTT 3228/4885CA1 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.